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Poster Session-II 127Primitive quiescent CD341 cells in chronic myeloid leukemia
(CML) are relatively resistant to tyrosine kinase inhibitors, which
may explain the persistence of detectable BCR-ABL transcripts fol-
lowing treatment with these agents. Conversely, allogeneic stem
cell transplantation (SCT) can eradicate residual CML, suggesting
that quiescent stem cells are eliminated by graft-versus-leukemia
(GVL) effects. We studied the progeny of CD341 cells after 4
days culture in serum-free media supplemented with interleukin-3,
interleukin-6, stem cell factor, granulocyte-colony stimulating factor
and Flt-3 ligand in 14 CML patients who subsequently received T
cell depleted SCT from their HLA-identical sibling donors. Cycling
CD34-negative and CD341, and non-cycling quiescent CD341
CML cells were isolated by fluorescence activated cell sorting. Fluo-
rescence in situ hybridization in 7 representative CML patients re-
vealed over 80% BCR-ABL positivity in both quiescent and
cycling CD341 and CD34-negative populations. The expression
of BCR-ABL was the same in both cycling and quiescent CD341
cell populations. Quiescent CD341 cells from CML patients were
lysed by natural killer (NK) cells from their donors, which had
been expanded after 11–13 days culture with interleukin-2 and irra-
diated EBV-LCL.QuiescentCD341 cells were less susceptible than
their cycling CD341 and CD34-negative counterparts to NK cyto-
toxicity. Compared to cycling populations, quiescent CD341 cells
from CML patients had higher expression of tumor necrosis fac-
tor-related apoptosis-inducing ligand (TRAIL) receptors. Previous
studies have demonstrated that bortezomib can sensitize malignant
cells to NK-cell TRAIL (Lundqvist et al Cancer Res 2006). Bortezo-
mib treatment of quiescent CD341 CML cells enhanced their kill-
ing by expanded donor NK cells. This increased sensitivity to NK-
cytotoxicity correlated with upregulation of TRAIL receptor DR4
on the surface of quiescent CD341 CML cells. Bortezomib did
not significantly affect the expression of MHC Class I, MIC A/B
or Fas (CD95) on CD341 quiescent or cycling cells. These results
suggest that adoptive transfer of in vitro expanded donor NK cells
with concomitant administration of bortezomib to the recipient
may enhance cytotoxicity to quiescent CD341 cells and may im-
prove NK-mediated GVL effects. This may be particularly applica-
ble to CML patients who are transplanted in more advanced stage
disease, and are at a greater risk of relapse.354
DISMAL RESPONSE TO HIGH DOSE METHYLPREDNISOLONE (MP) AFTER
FAILURE TO RESPOND TO STANDARD DOSE IN PEDIATRIC HEMATOPOI-
ETIC STEM CELL TRANSPLANTATION (HSCT) PATIENTS WITH ACUTE
GRAFT-VERSUS-HOST-DISEASE (AGVHD)
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Introduction: Corticosteroids remain the primary therapy for
aGVHD. The reported response rate to standard treatment (IV
MP 2mg/kg/day for 14 days then tapered) is 70%. Patients who
are refractory to standard treatment may be treated with high dose
MP. We evaluated the response to high dose MP in children with
aGVHD refractory to standard dose MP.
Methods:Children included in this evaluation underwent HSCT
between June 1, 2002 and July 31, 2006; did not receive MP for
aGVHD prophylaxis; developed $ grade II aGVHD; and received
MP 2mg/kg/day as initial therapy. Response to aGVHD therapy, al-
ternate aGVHD treatment, adverse effects attributed to MP and
overall outcomes were documented.
Results: 50 children (29 male; mean age 8.9yrs (range 0.3–17yrs))
developed aGVHD during the study period. The median time to di-
agnosis of aGVHD $ grade II was 18 days (range 10–60 days). 34
children had single organ involvement alone; 36 (72%) responded
to standard dose MP including 29 of 34 children with aGVHD in-
volving a single organ. Of the 14 children who failed to respond to
standard treatment, 12 children received high dose MP ($20mg/
kg/day) for 3 consecutive days followed by tapering dose. When
high dose MP was started, 10 patients had skin, 8 gut, 7 liver and 1
lung aGVHD. 11 patients had $ grade III aGVHD when high
dose MP was started. 10 patients received high dose MP at a median
of 11 days (range 3–18days) after starting standard treatment while 2patients receivedhighdoseMPafter other non-steroid therapy failed.
Only one patient with grade III aGVHD (stage 3 skin, stage 2 liver)
had complete response. 2 patients had partial response but flared
when MP was tapered. All patients who failed high dose MP needed
further salvage therapy. All children who receivedMP developed hy-
pertension and required antihypertensivemedication. 16 childrende-
veloped hyperglycemia (7 on high dose MP); 5 required insulin.
While on high-dose or tapering of high-doseMP, 5 developed severe
infection (2 fungal, 2 adenovirus, 1 bacterial). 22 out of the 36 patients
who responded to standard treatmentwere available for follow-up; 13
(60%) are alive (median follow-up:39mos). 6 children (50%) who re-
ceived high dose MP therapy died (median follow-up:46mos).
Conclusions: Children with aGVHD refractory to standard dose
MP who subsequently receive high dose MP do not respond and ex-
perience significant adverse effects. Other salvage therapy should be
considered in these patients.355
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N-acetyl-L-cysteine (NAC) is a thiol antioxidant which stimulates
glutathione synthesis in cells. Several studies indicate that NAC ex-
erts effects on the immune system in vitro, although with conflicting
results. Whereas some studies indicate that NAC has an inhibitory
effect on T cell proliferation and activation of NF-kB, others suggest
an activating effect. The ability of NAC to protect cells against oxi-
dative stress by inducing glutathione has provided a rationale for us-
ing it to prevent veno-occlusive disease of the liver and liver toxicity
after allogeneic stem cell transplantation (ASCT). Unfortunately,
a prospective randomized study failed to show a positive effect of
NAC on hepatotoxicity in ASCT patients. However, we observed
that patients who received NAC as a therapy to treat liver toxicity
(n 5 73) had an increased prevalence of acute GvHD compared to
patients who had been randomized to not receive NAC (n 5 87)
(P 5 0.04), indicating that NAC has an immunostimulatory effect
in vivo. Importantly, the NAC-treated group only had an increased
risk of grade II acute GvHD (30%) compared to the control group
(10%), whereas severe acute GvHD grades III-IV in the groups
were 8% vs 14%, respectively. These observations prompted us to
thoroughly study the effect of NAC on T cell mediated immunity
in vitro. We have found that low levels of NAC (0.4–3.2 mM) poten-
tiate T cell proliferation and upregualtion of activation markers in
response to alloantigens, whereas high concentrations (12.5–50
mM) are highly suppressive, whichmight explain the previously pub-
lished conflicting data. Furthermore, T cells that have been stimu-
lated in the presence of high concentrations of NAC (25 mM) in
a primary mixed lymphocyte reaction (MLR) respond more vigor-
ously when restimulated in a secondary MLR without NAC, com-
pared to control secondary MLR which had been cultured without
NAC during both stimulations. Preliminary data indicate that this
observation partly can be explained by that NAC render T cells
less apoptotic, and that T cells respond robustly when NAC has
been metabolized. To summarize, we have found that NAC has an
immunostimulatory effect on T cells under certain conditions,
both in vitro and in vivo. These observations might be of clinical im-
portance, as NAC potentially could be used as a therapeutic agent to
promote T cell mediated immunity in immunocompromized ASCT
patients with relapse of the underlying malignant disease.356
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128 Poster Session-IIStandard primary therapy for acute graft-vs.-host disease
(GVHD) is systemic corticosteroids, but failure of systemic steroids
to control acute GVHD is common and can result in very high non-
relapse mortality. Overall, fewer than 30% of patients with systemic
steroid resistant GVHD have complete or partial responses to avail-
able therapy, and 1 year survival remains 15% or less. There has been
no generally accepted therapy for systemic steroid-refractory acute
GVHD. Although little data on localized therapy for GVHD is pub-
lished, intra-arterial injection of high-dose corticosteroids appears to
be a viable option and sporadic publications have demonstrated sev-
eral positive outcomes in patients receiving intra-arterial steroids.
We report on 17 patients with systemic steroid resistant GVHD
who have been treated with intra-arterial injections of high-dose cor-
ticosteroids at our institution in the past 2 years. A total of 23 treat-
ments were performed with only three patients receiving more than
one treatment. Sixteen of the patients received treatment for GI
GVHD, of which three had concomitant hepatic involvement.
One received treatment for hepatic GVHD only. The patient with
isolated hepatic GVHD received treatments into the hepatic arteries
and all patients with GI GVHD received treatments into the supe-
rior and inferior mesenteric arteries. Six of the patients (35%) dem-
onstrated no response, and of those 3 died of GVHD and 3 died of
other complications. Five patients (29%) showed partial response.
Of these, 4 were discharged on TPN and oral meds 14 to 43 days af-
ter the intra-arterial treatment, the fifth patient became septic prior
to discharge and expired. The remaining six patients (35%) showed
complete response and were discharged on PO diet and oral meds 1
to 22 days after the intra-arterial treatment. No immediate treatment
or procedure related complications were noted. These preliminary
results reinforce that direct intra-arterial injection of methylprednis-
olone appears to be effective and safe in patients that have proven to
be resistant to systemic steroids. In two patients, one with a complete
and the other with a partial response, there was recurrence of
GVHD. These patients raise the question of whether more than
one initial treatment may be helpful in preventing recurrence.
Larger, prospective studies need to be conducted to further evaluate
this promising approach to systemic steroid refractory GVHD.
Patient Characteristics, Response, and Current Status
Location Duration Number CurrentAge/
Sex Diagnosisof
DiseasePrior
Treatmentto
Responseof
Treatments ResponseStatus (days
post IAS)63/F NHL GI IVS, INF 14 days 1 PR no GVHD (713)48/M NHL GI IVS, ATG,
INF x2, MSC21 days 1 PR cGVHD (564)58/M NHL GI IVS 12 days 1 PR D, ARDS, no
GVHD (42)41/F MM GI IVS, ATG 43 days 1 PR D, ARDS, no
GVHD (53)50/F AA GI IVS, ATG 12 days 1 CR cGVHD of
Lungs, no GI
GVHD (562)70/M NHL Hepatic IVS, ATG 22 days 1 CR no GVHD (735)60/M NHL GI IVS, INF 1 day 1 CR no GVHD (568)50/F NHL GI IVS 19 days p 1st,
7 days p 2nd2 CR no GVHD (700)71/M NHL GI IVS, INF x4,
ATG5 NR D, GVHD (15)55/M NHL GI IVS 7 days 1 CR D - perforation
secondary to
CMV colitis
(404)39/F NHL GI IVS 1 NR D, GVHD, CMV
colitis (56)70/F NHL GI IVS 1 NR D, GVHD,
sepsis (50)38/M NHL GI IVS 1 NR D, GVHD (15)60/F NHL GI IVS, INF 24 days 1 CR D, recurrent
GVHD (498)59/M NHL GI IVS, INF 2 NR D, GVHD (11)61/F MDS/
NHLGI IVS 14 days 1 PR D, sepsis, no
GVHD (34)(Continued ). (Continued )Age/
Sex DiagnosisLocation
of
DiseasePrior
TreatmentDuration
to
ResponseNumber
of
Treatments ResponseCurrent
Status (days
post IAS)50/M MDS/
NHLGI IVS, ATG 1 NR D, GVHD,
sepsis (32)IAS indicates intra-arterial steroids; NHL, non hodgkin’s lymphoma; MM,
multiple myeloma; AA, aplastic anemia; MDS, myelodysplastic syn-
drome; GI, gastrointestinal; IVS, intra-venous steroids; ATG, anti-thymo-
cyte globulin; INF, infliximab; MSC, mesenchymal stem cells; PR, partial
response; CR, complete response; NR, no response; D, dead; GVHD,
graft-vs-host disease; cGVHD, chronic GVHD; ARDS, acute respiratory
distress syndrome; CMV, cytomegalovirus.357
THERAPY OF STEROID-REFRACTORY ACUTE GvHD WITH CD52 ANTI-
BODY ALEMTUZUMAB IS EFFECTIVE AND SAFE
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Although in recent years techniques of allogeneic hematopoietic
stem cell transplantation have improved considerably to allow the
use of this procedure even for elderly and less fit patients, severe
graft-versus-host disease (GvHD) remains themain obstacle to apply
this therapeutic modality. Still, no standard therapy has been identi-
fied once a patient has developed severe acute GvHD and is refrac-
tory to high-dose steroids. The pre-emptive use of CD52 antibody
alemtuzumab as part of the conditioning regimen may lead unneces-
sarily to relapse and increased infection rates. Commercially avail-
able alemtuzumab was used in 16 patients now evaluable, age
range 13 to 68 years, with GvHD grade III and IV refractory to at
least 7 days of high-dose steroids. Patients had undergone stem
cell transplantation from family donors (n5 7) or matched unrelated
donors (n 5 9). Four had 1 or 2 antigen mismatch. All patients had
severe gut and/or liver involvement. Initially, in three patients in
rather critical situations start doses of alemtuzumab in the range of
70mg to 80mg (total) were applied in fractions over several days
and repeated after 3 to 4 weeks. Impressive responses, such as biliru-
bin levels of 48mg/dl returning to normal within several weeks, were
encouraging, but virus reactivation and bacterial infections were
seen. This finding and considering the limited quantities of lym-
phoid tissue present early after transplantation requiring less anti-
body, the starting dose was reduced to 20 to 33 mg in the second,
and 5–10mg in the third cohort, repeated every 2 to 3 weeks. CR,
or near CR, were obtained in 11 of 13 patients of these two dosage
groups. The longest follow-up is 138 months. Chronic GvHD
was frequently observed. Pronounced lymphocyte depletion seems
inevitable for efficacy, but infectious complications were limited.
Thus, despite the need for close observation for infectious complica-
tions, alemtuzumab given sequentially in moderate doses has a sub-
stantial activity in severe steroid-refractory acute GvHD.358
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Background:Extracorporeal photopheresis (ECP) is used to treat
cGVHD, but its mechanism has not been fully defined. One model
for the mechanism of ECP in cGVHD is dendritic cell (DC) deple-
tion andT-cell modification.We tested this hypothesis by determin-
ing the numbers of circulating DCs and T-cells prior to ECP and
